Quoin insider Stonepine files Form 4 with no trades

Quoin Pharmaceuticals, Ltd. reported a Form 4 filing by Stonepine Capital Management, LLC, identified as a ten percent owner of QNRX.

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. reported a Form 4 filing by Stonepine Capital Management, LLC, identified as a ten percent owner of QNRX. The summarized data shows no reported purchases, sales, exercises, gifts, or other share transactions in this filing.

Key Terms

Form 4, ten percent owner, derivative transactions, netBuySellDirection

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

ten percent owner regulatory

""is_ten_percent_owner": 1"

derivative transactions financial

""derivativeTransactionCount": 0"

Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.

netBuySellDirection financial

""netBuySellDirection": "neutral""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 4 for QNRX show about Stonepine Capital Management, LLC?

The Form 4 lists Stonepine Capital Management, LLC as a ten percent owner of Quoin Pharmaceuticals, Ltd., but shows no reported share purchases, sales, exercises, gifts, or restructurings in the summarized transaction data.

Were any QNRX shares bought or sold in this Stonepine Capital Form 4?

No. The transaction summary for Stonepine Capital Management, LLC shows zero reported buy, sell, exercise, gift, tax withholding, or restructuring transactions, indicating no share activity was reported in this particular Form 4 filing.

Does the QNRX Form 4 include any derivative transactions by Stonepine Capital?

No derivative transactions are shown. The filing’s derivative transaction count and exercise-related fields are all zero, indicating no option exercises, conversions, or other derivative-related activities were reported for Stonepine Capital Management, LLC.

What is Stonepine Capital Management, LLC’s status in relation to QNRX?

Stonepine Capital Management, LLC is identified as a ten percent owner of Quoin Pharmaceuticals, Ltd. in this Form 4. That status can trigger ongoing reporting obligations for changes in ownership under SEC rules, even when a specific filing reports no transactions.

Does this QNRX Form 4 suggest any change in insider sentiment?

The Form 4 does not indicate a change in sentiment. With zero reported share purchases, sales, or derivative exercises, the filing reflects no new ownership transactions for Stonepine Capital Management, LLC in the summarized data provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 01:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonepine Capital Management, LLC

(Last) (First) (Middle)

2900 NW CLEARWATER DRIVE

SUITE 100-11

(Street)

BEND OREGON 97703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

On March 26, 2026, the Issuer filed a Form 10-K reporting it has 63,126,930 Ordinary Shares outstanding, represented by 1,803,626 American Depositary Shares outstanding. All of the warrants owned by the reporting person are subject to a 9.99% beneficial ownership limitation. As a result of the change in the number of Ordinary Shares outstanding, the reporting person has ceased to beneficially own more than 10% of the outstanding Ordinary Shares.

	/s/ Jon M. Plexico, Managing Member of Stonepine Capital Management, LLC	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)